25 Feb 2016 --- Nestlé Health Science has made a strategic investment of US$ 42.5 million in Pronutria Biosciences (Cambridge, MA, USA) to advance amino acid and health research. Pronutria is pioneering a pipeline of oral therapeutic and nutritional biologics, called Pronutrein proteins. These target imbalances in amino acid profiles – the foundation of human protein – that are now understood to have underlying roles in a range of health conditions (e.g. neurological, muscle and liver disorders).
